<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="215531">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00279721</url>
  </required_header>
  <id_info>
    <org_study_id>18916</org_study_id>
    <nct_id>NCT00279721</nct_id>
  </id_info>
  <brief_title>Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.</brief_title>
  <official_title>Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberta Health Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <brief_summary>
    <textblock>
      Resected well-differentiated thyroid neoplasms with at least one high risk feature will
      receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control
      rate at 2 years will be recorded.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Resected well-differentiated thyroid neoplasms with at least one high risk feature will
      receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control
      rate at 2 years will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>toxicity according to RTOG criteria</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>locoregional control</measure>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Thyroid Neoplasms</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IMRT</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  resected well-differentiated throid cancer with at least one high risk feature for
             locoregional recurrence

        Exclusion Criteria:

          -  medullary or anaplastic thyroid cancer, unresectable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harold Lau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tom Baker Cancer Centre</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>January 18, 2012</lastchanged_date>
  <firstreceived_date>January 18, 2006</firstreceived_date>
  <keyword>thyroid neoplasms</keyword>
  <keyword>intensity modulated radiation</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
